Simone Mocellin
西蒙·莫切林
MD, PhD
Professor of Surgical Oncology and Director, Melanoma Unit外科肿瘤学教授兼黑色素瘤科主任
👥Biography 个人简介
Simone Mocellin is a European leader in melanoma targeted therapy and surgical oncology. He has contributed extensively to clinical and translational research on BRAF/MEK inhibitors and has led meta-analyses shaping evidence-based melanoma treatment guidelines internationally.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
BRAF/MEK Inhibitor Clinical Outcomes in Melanoma
Conducted systematic reviews and meta-analyses of BRAF and MEK inhibitor trials in advanced melanoma, providing evidence synthesis informing treatment guidelines and combination strategies.
Telomerase as a Cancer Target
Investigated telomerase biology in cancer and performed comprehensive meta-analyses of telomerase-targeted therapies, contributing to understanding of telomere maintenance as a therapeutic vulnerability.
Representative Works 代表性著作
Telomerase and the search for the end of cancer
Trends in Molecular Medicine (2013)
Reviewed telomerase as a universal cancer target, synthesizing preclinical and clinical evidence for telomere-targeting strategies in oncology.
Targeted therapy for melanoma: a meta-analysis of randomized controlled trials
Annals of Oncology (2015)
Large-scale meta-analysis quantifying survival benefits of BRAF/MEK inhibitor combinations versus monotherapy in BRAF-mutant advanced melanoma patients.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Sebastian Bauer
University Hospital Essen (Universitätsklinikum Essen)
Suzanne George
Dana-Farber Cancer Institute / Harvard Medical School
Marcia S. Brose
Sidney Kimmel Cancer Center, Thomas Jefferson University
Lori J. Wirth
Massachusetts General Hospital, Harvard Medical School
关注 西蒙·莫切林 的研究动态
Follow Simone Mocellin's research updates
留下邮箱，当我们发布与 Simone Mocellin（University of Padova）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment